AstraZeneca PLC (AZN) – Growth from ex-COVID medicines

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

AstraZeneca PLC (AZN) (Q1FY23)

Highlights

AstraZeneca’s Revenue is stable at $10,879m, despite a decline of $1,460m from COVID-19 medicines. Excluding COVID-19 medicines, Total Revenue increased 15% and Product Sales increased 16%. We believe that AZN is fundamentally strong and the growth from ex COVID product will drive the long term revenue of the organization.

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates